RESUMO
INTRODUCTION: Lung cancer is one of the most common cancer malignancies and the principal cause of cancer-associated deaths worldwide. Non-small cell lung cancers (NSCLCs) account for more than 80% of all lung cancer cases. Recent studies showed that the genes of the integrin alpha (α) (ITGA) subfamily play a fundamental role in various cancers. However, little is known about the expression and roles of distinct ITGA proteins in NSCLCs. METHODS: Gene Expression Profiling Interactive Analysis and UALCAN (University of ALabama at Birmingham CANcer) web resources and The Cancer Genome Atlas (TCGA), ONCOMINE, cBioPortal, GeneMANIA, and Tumor Immune Estimation Resource databases were used to evaluate differential expression, correlations between the expression levels of individual genes, the prognostic value of overall survival (OS) and stage, genetic alterations, protein-protein interactions, and the immune cell infiltration of ITGAs in NSCLCs. We used R (v. 4.0.3) software to conduct gene correlation, gene enrichment, and clinical correlation of RNA sequencing data of 1016 NSCLCs from TCGA. To evaluate the expression of ITGA5/8/9/L at the expression and protein levels, qRT-PCR, immunohistochemistry (IHC), and hematoxylin and eosin (H&E) were performed, respectively. RESULTS: Upregulated levels of ITGA11 messenger RNA and downregulated levels of ITGA1/3/5/7/8/9/L/M/X were observed in the NSCLC tissues. Lower expression of ITGA5/6/8/9/10/D/L was discovered to be expressively associated with advanced tumor stage or poor patient prognosis in patients with NSCLC. A high mutation rate (44%) of the ITGA family was observed in the NSCLCs. Gene Ontology functional enrichment analyses results revealed that the differentially expressed ITGAs could be involved in roles related to extracellular matrix (ECM) organization, collagen-containing ECM cellular components, and ECM structural constituent molecular functions. The results of the Kyoto Encyclopedia of Genes and Genomes analysis revealed that ITGAs may be involved in focal adhesion, ECM-receptor interaction, and amoebiasis; the expression of ITGAs was significantly correlated with the infiltration of diverse immune cells in NSCLCs. ITGA5/8/9/L was also highly correlated with PD-L1 expression. The validation results for marker gene expression in NSCLC tissues by qRT-PCR, IHC, and H&E staining indicated that the expression of ITGA5/8/9/L decreased compared with that in normal tissues. CONCLUSION: As potential prognostic biomarkers in NSCLCs, ITGA5/8/9/L may fulfill important roles in regulating tumor progression and immune cell infiltration.
Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Humanos , Carcinoma Pulmonar de Células não Pequenas/genética , Neoplasias Pulmonares/genética , PrognósticoRESUMO
Objective: This study aimed to design a nomogram survival prediction by means of the figures retrieved from the Surveillance, Epidemiology, and End Results (SEER) source bank, and to predict the overall survival (OS) of patients with stage IIA non-small cell lung cancer (NSCLC) after surgery. Methods: Data for 4511 patients who had been diagnosed with postoperative stage IIA NSCLC were collected from the SEER databank, while information on 528 patients was acquired from the Chongqing University Cancer Hospital for the external validation cohort. The independent risk factors that affected the prognosis were identified using a multivariate Cox proportional hazards regression model (also used to conduct a nomogram). A survival analysis between the low- and the high-risk groups was performed using the Kaplan-Meier method. Furthermore, a subgroup analysis was conducted of the two groups using the Kaplan-Meier method to determine whether the patients had received adjuvant chemotherapy. Results: The following five variables were integrated into the nomogram: sex (female: HR 1.73, 95% CI 0.64-0.83), age (≥60: HR 1.61, 95% CI 1.39-1.87), differentiation grade (grade II: HR 2.19, 95% CI 1.66-2.88; grade III: HR 2.65, 95% CI 2.00-3.51; grade IV: HR 3.17, 95% CI 1.99-5.03), surgery (lobectomy: HR 0.72, 95% CI 0.59-0.86), and lymph node resection (>12: HR 0.82, 95% CI 0.70-0.96). Furthermore, the patients selected were categorized into high- and low-risk groups. The OS rate was significantly lower in the high-risk group than in the low-risk group (P < 0.001). Finally, adjuvant chemotherapy was highly correlated with OS in the high-risk set (P = 0.035); however, adjuvant chemotherapy was not related to OS in the low-risk set. Conclusion: A nomogram was created as a reliable, convenient scheme that could predict OS, and it was determined that the high-risk feature patients identified by the nomogram gained benefits from adjuvant chemotherapy.
RESUMO
The deregulation of circular RNAs (circRNAs) is involved in cancer development. CircRNA polo-like kinase 1 (circPLK1) was reported to promote breast cancer development. However, the role of circPLK1 in malignant pleural mesothelioma (MPM) is unclear. The expression of circPLK1, miR-1294, and high mobility group AT-hook 1 (HMGA1) mRNA was measured by quantitative real-time PCR (qPCR). Cell viability was detected by CCK-8 assay. Colony formation ability was monitored by colony formation assay. Cell proliferation was detected by EdU assay. Cell migration and cell invasion were monitored by transwell assay. Cancer cell stemness was investigated by sphere formation assay. The protein levels of marker proteins and HMGA1 expression were measured by western blot analysis. The binding relationship between miR-1294 and circPLK1 or HMGA1 was validated by pull-down assay, dual-luciferase reporter assay or RIP assy. Animal study was performed to disclose the role of circPLK1 in vivo. Exosomes were identified by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). CircPLK1 was upregulated in MPM tumor tissues and cell lines. CircPLK1 knockdown suppressed the proliferation, migration, invasion and stemness of MPM cells. CircPLK1 contained a binding site for miR-1294 and thus bound to miR-1294 to sequester its expression. Inhibition of miR-1294 reversed the effects of circPLK1 knockdown. HMGA1 was a target of miR-1294, and circPLK1 bound to miR-1294 to increase the expression of HMGA1. MiR-1294 restoration also suppressed the proliferation, migration, invasion and stemness of MPM cells, while these effects were abolished by HMGA1 overexpression. In addition, circPLK1 knockdown inhibited tumor growth in vivo. CircPLK1 was overexpressed in exosomes derived from serum of MPM patients. CircPLK1 knockdown inhibited MPM cell proliferation, migration, invasion and stemness by targeting the miR-1294/HMGA1 pathway.
Assuntos
Mesotelioma Maligno , MicroRNAs , Animais , Carcinogênese/genética , Carcinógenos , Regulação Neoplásica da Expressão Gênica , Proteína HMGA1a/genética , Proteína HMGA1a/metabolismo , MicroRNAs/metabolismo , RNA Circular , Fatores de Transcrição/genéticaRESUMO
In order to understand the removal characteristics of Cl- (chloride ion) in the fly ash from municipal solid waste incineration, so as to realize the harmless treatment of fly ash. The fly ash washing treatment experimental system was designed and built. The single factor experiments were used to explore the effect of liquid-to-solid ratio, washing time and temperature on the leaching rate of Cl- in the fly ash. The best experimental parameters of fly ash washing were obtained. At the same time, the microscopic morphology and crystal phase composition of fly ash before and after washing were explored. The results showed that the maximum removal rate of Cl- in the fly ash was 88.72% when the liquid-to-solid ratio was 8:1, the washing time was 5 min and the washing temperature was 70 â. It can be seen from the scanning electron microscope (SEM) image that most of the irregularly shaped square fly ash particles gradually transformed into regular spherical or elliptical shapes after washing. The X-ray diffractometer (XRD) results proved that the chlorine salt content in the fly ash after washing was significantly reduced, and the CaSO4â¢2(H2O), SiO2, CaCO3 and other substances were formed.
Assuntos
Metais Pesados , Eliminação de Resíduos , Carbono/química , Cloretos/química , Cinza de Carvão , Incineração/métodos , Material Particulado/química , Dióxido de Silício , Resíduos Sólidos , TemperaturaRESUMO
Delvestidine (DLTD) is a monomeric compound isolated from Aconitum leucostomum Worosch, a widely used medicine for local treatment of rheumatoid arthritis (RA). Studies have shown that Aconitum leucostomum Worosch. can inhibit maturation of bone marrow-derived dendritic cells (BMDCs). Further, microRNAs (miRNAs) have regulatory effects on DC maturity and function. However, the mechanism underlying DLTD effects on DC maturity and RA remains to be elucidated. This study investigated whether DLTD-mediated inhibition of DC maturation is regulated by miRNAs. LPS-induced mature BMDCs were treated with DLTD for 48 h. CD80 and CD86 expression on BMDCs was detected by flow cytometry, and levels of inflammatory factors IL-6, IL-23, IL-1ß, and TNF-α were detected by ELISA and PCR. Further, gene expression and miRNA expression profiles were investigated by bioinformatics analysis and verified by PCR. DLTD was found to inhibit CD80 and CD86 expression on the surface of BMDCs and secretion of inflammatory factors IL-6, IL-23, IL-1ß, and TNF-α. In total, 54 differentially expressed miRNAs were detected, including 29 up-regulated and 25 down-regulated miRNAs after DLTD treatment. Analysis of biological information revealed that the differentially expressed target genes mainly regulated biological processes, including cell differentiation, cell cycle, and protein kinase complexes. Additionally, miR-511-3p downstream targets Calcr, Fzd10, and Eps8, were closely related to BMDCs maturation. DLTD may induce BMDCs maturity through regulation of miRNAs that affect Calcr, Fzd10, and Eps8 gene signals.
Assuntos
Aconitum/química , Células da Medula Óssea/imunologia , Células da Medula Óssea/metabolismo , Células Dendríticas/imunologia , Células Dendríticas/metabolismo , MicroRNAs/imunologia , MicroRNAs/metabolismo , Proteínas Adaptadoras de Transdução de Sinal/efeitos dos fármacos , Proteínas Adaptadoras de Transdução de Sinal/genética , Animais , Antígeno B7-1/efeitos dos fármacos , Antígeno B7-1/metabolismo , Antígeno B7-2/efeitos dos fármacos , Antígeno B7-2/metabolismo , Proteína Semelhante a Receptor de Calcitonina/efeitos dos fármacos , Proteína Semelhante a Receptor de Calcitonina/genética , Diferenciação Celular , Células Cultivadas , Biologia Computacional , Citocinas/genética , Citocinas/metabolismo , Receptores Frizzled/efeitos dos fármacos , Receptores Frizzled/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Lipopolissacarídeos/toxicidade , Camundongos Endogâmicos BALB C , MicroRNAs/genética , Antígenos de Histocompatibilidade Menor/efeitos dos fármacos , Antígenos de Histocompatibilidade Menor/genética , Receptores de Citocinas/efeitos dos fármacos , Receptores de Citocinas/genéticaRESUMO
Melanoma is a malignant tumor that arises from epidermal melanocytes with high morbidity and mortality, and currently, there are no effective conventional genotoxic treatments or systematic treatment. Increasing evidence shows that n-3 polyunsaturated fatty acids (PUFAs) exhibit anti-melanoma activity, but their anti-melanoma mechanism remains elusive. Here, C57BL/6 mice were injected with B16F10 melanoma cells via a tail vein to establish a lung metastasis model. n-3 PUFAs were significantly increased in lung metastatic tissues from mice treated with algal oil, especially rich in docosahexaenoic acid (DHA). Algal oil treatment significantly suppressed pulmonary metastases and outgrowth of melanoma cells, which was associated with autophagy induction, as evidenced by an increase in LC3-II levels. In addition, algae oil-triggered autophagy was mediated by inactivation of the mammalian target of rapamycin (mTOR) and p38 mitogen-activated protein (MAP) kinase, and activation of c-Jun N-terminal kinases (JNKs), which led to a decrease in p62 accumulation and decreased secretion of proinflammatory cytokine interleukin-1ß (IL-1ß). These results suggest that algal oil exerts its antitumourigenic activities via autophagy-mediated p62 elimination and anti-inflammatory properties.
Assuntos
Autofagia/efeitos dos fármacos , Clorófitas/química , Ácidos Graxos Ômega-3/administração & dosagem , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/fisiopatologia , Melanoma/patologia , Óleos de Plantas/administração & dosagem , Animais , Linhagem Celular Tumoral , Ácidos Graxos Ômega-3/análise , Humanos , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/secundário , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Metástase Neoplásica/tratamento farmacológico , Óleos de Plantas/análise , Serina-Treonina Quinases TOR/genética , Serina-Treonina Quinases TOR/metabolismoRESUMO
Nonalcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus (T2DM) are highly prevalent diseases and are closely associated, with NAFLD being present in the majority of T2DM patients. In Asian traditional medicine, Mori Cortex is widely used for the treatment of diabetes and hyperlipidemia. However, whether it has a therapeutic effect on T2DM associated with NAFLD is still unknown. The present study showed that the oral treatment with Mori Cortex extract (MCE; 10 g·kg-1·d-1) lowered the blood lipid levels and reversed insulin resistance (IR) in high fat-diet/streptozotocin-induced type 2 diabetes in rats. The expression levels of sterol receptor element-binding protein-1c (SREBP-1c) and carbohydrate-responsive element binding protein (ChREBP), which are involved in steatosis in NAFLD rats, were measured in the liver samples. MCE decreased the protein and mRNA expression levels of SREBP-1c and ChREBP. In conclusion, down-regulation of SREBP-1c and ChREBP might contribute to the protective effect of MCE on hepatic injury and IR in the rats with T2DM associated with NAFLD.
Assuntos
Diabetes Mellitus Tipo 2/metabolismo , Regulação para Baixo/efeitos dos fármacos , Resistência à Insulina/fisiologia , Morus , Hepatopatia Gordurosa não Alcoólica/metabolismo , Extratos Vegetais/farmacologia , Alanina Transaminase/sangue , Animais , Aspartato Aminotransferases/sangue , Fatores de Transcrição de Zíper de Leucina e Hélice-Alça-Hélix Básicos/genética , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/induzido quimicamente , Diabetes Mellitus Tipo 2/tratamento farmacológico , Dieta Hiperlipídica/efeitos adversos , Modelos Animais de Doenças , Insulina/sangue , Metabolismo dos Lipídeos/efeitos dos fármacos , Metabolismo dos Lipídeos/genética , Fígado/efeitos dos fármacos , Fígado/fisiopatologia , Masculino , Hepatopatia Gordurosa não Alcoólica/sangue , Hepatopatia Gordurosa não Alcoólica/induzido quimicamente , Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico , Fitoterapia , Extratos Vegetais/uso terapêutico , Ratos , Ratos Sprague-Dawley , EstreptozocinaRESUMO
OBJECTIVE: To evaluate the efficacy of α-lipoic acid (ALA) plus epalrestat combination therapy in the treatment of diabetic peripheral neuropathy (DPN). DATA SOURCES: The electronic databases of PubMed, Medline, Embase, the Cochrane Library, the Chinese National Knowledge Infrastructure, the Wanfang Database and the Chinese Biomedical Database were used to retrieve relevant studies without language restrictions. The search was conducted from the inception of each database to 7 October 2016. The key terms were (diabetic peripheral neuropathy or diabetic neuropathy or DPN) AND (α-lipoic acid or lipoic acid or thioctic acid) AND epalrestat. DATA SELECTION: All of the eligible studies met the following inclusion criteria: (1) Randomized controlled trials that compared efficacy and safety of epalrestat plus ALA combination therapy versus epalrestat or ALA monotherapy in patients with DPN. (2) The minimum duration of treatment was 2 weeks. (3) The DPN patients were diagnosed using the World Health Organization standardized type 2 diabetes mellitus and DPN criteria. (4) Studies contained at least one measure that could reflect the efficacy of the drug and nerve conduction velocities. Studies in which the control group used epalrestat or ALA combined with other drugs were excluded. Statistical analyses were performed using STATA software for meta-analysis. OUTCOME MEASURES: The primary outcomes were the therapeutic efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV and peroneal SNCV. RESULTS: Twenty studies with 1894 DPN patients were included, including 864 patients in the ALA plus epalrestat group, 473 in the ALA group and 557 in the epalrestat group. The efficacy of ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies (RR = 1.29, 95% CI: 1.21-1.38; RR = 1.43, 95% CI: 1.34-1.54, respectively). ALA plus epalrestat combination therapy also significantly improved median MNCV (WMD = 5.41, 95% CI: 2.07-8.75), median SNCV (WMD = 5.87, 95% CI: 1.52-10.22), peroneal MNCV (WMD = 5.59, 95% CI: 2.70-8.47) and peroneal SNCV (WMD = 4.57, 95% CI: 2.46-6.68). CONCLUSION: : ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies for clinical efficacy and nerve conduction velocities in patients with DPN.
RESUMO
INTRODUCTION: This subgroup analysis of data from the 16-week Lantus Registry Study in China investigated the characteristics of patients with type 2 diabetes mellitus (T2DM) associated with clinical benefits of transitioning therapy from premixed insulin to insulin glargine (100 U/ml) plus oral antidiabetic drugs (OADs). METHODS: The modified intention-to-treat population of the Lantus Registry Study, comprising 1847 patients with T2DM, were included in the current subgroup analyses. Enrolled patients were divided into subgroups based on efficacy variables of endpoint glycated hemoglobin (HbA1c), endpoint fasting plasma glucose (FPG), and change in HbA1c from baseline. The baseline characteristics of those who did and did not achieve HbA1c <7.0% were compared, as were those with improvement, no change, or deterioration in HbA1c. Characteristics of patients who were unable to achieve HbA1c <7.0%, further grouped according to whether or not they achieved FPG ≤6.1 mmol/L, were also compared. Logistic regression analysis was used to identify factors associated with achieving HbA1c <7.0%. RESULTS: Comparison between subgroups demonstrated that patients with endpoint HbA1c <7.0% were significantly younger, with a shorter duration of diabetes and lower baseline FPG, HbA1c, body mass index, and dose of premixed insulin than patients with endpoint HbA1c ≥7.0%. Logistic regression analysis revealed a negative correlation between baseline age, HbA1c, FPG, and duration of diabetes with achieving HbA1c <7.0%. When stratified according to change in HbA1c, the improvement group was younger, with higher baseline HbA1c and a greater number of patients with duration of diabetes ≤5 years. Three-quarters of patients unable to achieve HbA1c <7.0% also failed to reach FPG ≤6.1 mmol/L. CONCLUSION: Younger patients with a shorter duration of diabetes and lower HbA1c, FPG, and premixed insulin dose following a switch in treatment to insulin glargine (100 U/ml) plus OADs from premixed insulin have greater potential to achieve HbA1c <7.0%. Poorly controlled patients with higher baseline HbA1c are most likely to experience an improvement in HbA1c following the switch in therapy. The majority of patients unable to achieve HbA1c <7.0% also failed to reach FPG ≤6.1 mmol/L, highlighting the importance of adequate titration of insulin glargine to achieve adequate FPG control, which can enable achievement of target HbA1c. FUNDING: Sanofi.
RESUMO
BACKGROUND: The human epidermal growth factor receptor-2 (HER2) genes have been described in a subset of non-small cell lung cancer (NSCLC). To help identify and treat these patients, we investigated the frequency, clinicopathologic characteristics, and clinical outcomes of patients who had NSCLC with or without HER2 insertions. METHODS: The mutational status of the HER2 (exons 19-20) gene was assessed in a cohort of 1875 patients with NSCLC. All patients were also analyzed for mutations in EGFR, KRAS, BRAF, ALK, RET, and ROS1. Clinical characteristics, including age, sex, smoking status, stage, histology, tumor size, differentiation, overall survival, and relapse-free survival, were collected. RESULTS: Among 1875 NSCLCs examined, 35 (1.9 %) were HER2 insertion. Compared with the HER2 insertion-negative group, patients with HER2 insertions were more likely to be never smokers (97.1 %, 34/35 patients, P < 0.001), significantly associated with female (91.4 %, 32/35 patients, P < 0.001), adenocarcinoma (91.4 %, 32/35 patients, P = 0.01), and with a tendency to be no more than 60 years of age (71.4 %, 25/35 patients, P = 0.051). CONCLUSIONS: HER2 insertion could define a distinct subset of NSCLC, which had a higher prevalence among females, nonsmokers, and adenocarcinoma. HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy.
Assuntos
Adenocarcinoma/genética , Carcinoma Pulmonar de Células não Pequenas/genética , Neoplasias Pulmonares/genética , Receptor ErbB-2/genética , Adenocarcinoma/patologia , Carcinoma Pulmonar de Células não Pequenas/patologia , Feminino , Humanos , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Mutagênese Insercional , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores SexuaisRESUMO
Malignant melanoma is the most lethal form of skin cancer. Although preclinical studies have shown that n-3 polyunsaturated fatty acids (PUFAs) are beneficial for prevention of melanoma, the molecular mechanisms underlying the protective effects of n3 PUFAs on melanoma remain largely unknown. In the present study, endogenously increased levels of n-3 PUFAs in the tumor tissues of omega3 fatty acid desaturase (fat1) transgenic mice was associated with a reduction in the growth rate of melanoma xenografts. This reduction in tumor growth in fat1 mice compared with wildtype controls may have been associated, in part, to the: i) Increased expression of Ecadherin and the reduced expression of its transcriptional repressors, the zinc finger Ebox binding homeobox 1 and snail family transcriptional repressor 1; ii) significant repression of the epidermal growth factor receptor/Akt/ßcatenin signaling pathway; and iii) formation of significant levels of n3 PUFAderived lipid mediators, particularly resolvin D2 and E1, maresin 1 and 15hydroxyeicosapentaenoic acid. In addition, vitamin E administration counteracted n3 PUFAinduced lipid peroxidation and enhanced the antitumor effect of n3 PUFAs, which suggests that the protective role of n3 PUFAs against melanoma is not mediated by n3 PUFAsinduced lipid peroxidation. These results highlight a potential role of n3 PUFAs supplementation for the chemoprevention of melanoma in highrisk individuals, and as a putative adjuvant agent in the treatment of malignant melanoma.
Assuntos
Caderinas/metabolismo , Proteínas de Caenorhabditis elegans/genética , Ácidos Graxos Dessaturases/genética , Ácidos Graxos Ômega-3/metabolismo , Melanoma/metabolismo , Neoplasias Cutâneas/metabolismo , beta Catenina/metabolismo , Animais , Caenorhabditis elegans/genética , Linhagem Celular Tumoral , Feminino , Masculino , Melanoma/patologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Transdução de Sinais , Pele/metabolismo , Pele/patologia , Neoplasias Cutâneas/patologiaRESUMO
The sex difference in the prevalence rates of diabetes and cardiovascular diseases (CVDs) among the middle-aged population in China remain largely unknown. Therefore, we analyzed differences in the prevalence of diabetes, self-reported CVDs, and some CVD risk factors among men and women in the middle-aged population (30-49 years) and in individuals aged 50 years and older using data from the China National Diabetes and Metabolic Disorders Study of 2007-2008. Middle-aged men appeared to have significantly a higher prevalence of diabetes and self-reported CVDs than middle-aged women (8.07% vs 5.06% for diabetes, P < 0.001; 0.64% vs 0.22% for CVDs, P < 0.001). Men also showed higher rates of central obesity, hypertension, and dyslipidemia than women (all P < 0.01). Compared with women, men were more likely to drink alcohol and smoke cigarettes but less likely to be under diet control. The sex-specific differences in prediabetes, CVD, and CVD risk factors between men and women were diminished or even reversed in the population aged 50 years and older. No sex-specific differences were found in the prevalences of a family history of diabetes, coronary heart disease, and hypertension (P > 0.05) in middle-aged population. Specific strategies to reduce modifiable risk factors for the prevention and control of diabetes and CVD may be warranted in this population.
Assuntos
Doenças Cardiovasculares/epidemiologia , Diabetes Mellitus/epidemiologia , Adulto , Fatores Etários , Consumo de Bebidas Alcoólicas/epidemiologia , Doenças Cardiovasculares/etiologia , China/epidemiologia , Estudos Transversais , Diabetes Mellitus/etiologia , Dieta Redutora/estatística & dados numéricos , Dislipidemias/epidemiologia , Feminino , Humanos , Hipertensão/epidemiologia , Masculino , Pessoa de Meia-Idade , Obesidade Abdominal/epidemiologia , Estado Pré-Diabético/epidemiologia , Prevalência , Fatores de Risco , Fatores Sexuais , Fumar/epidemiologiaRESUMO
Type 2 diabetes mellitus (T2DM) is a glucose metabolic disorder driven by both genetic and environmental factors. Recent DNA methylation studies have established that T2DM may be contributed by environmental factors through the regulation of DNA methylation. Human and animal model studies have made much progress on the interaction between DNA methylation of T2DM genes and environmental factors in multiple tissues. Current studies on DNA methylation of T2DM genes mainly focus on glucose and energy metabolism, inflammation, and so on. This review comprehensively introduces the DNA methylation studies for the genes involved in T2DM and its related environmental factors.
Assuntos
Diabetes Mellitus Tipo 2/genética , Interação Gene-Ambiente , Animais , Metilação de DNA , Diabetes Mellitus Tipo 2/metabolismo , Epigênese Genética , HumanosRESUMO
A simple high-performance liquid chromatographic method using ultraviolet detection was developed for the determination of praziquantel in bovine muscle. The sample was extracted with ethyl acetate, cleaned up by alumin B cartridge. Analyses were run at a flow-rate of 0.8 ml/min with the detector operating at a detection wavelength of 220 nm. The method is specific and sensitive, with a quantification limit of 0.02 mg/kg and a detection limit of 0.01 mg/kg. The standard calibration curve of drugs solution was linear in the range of 0.02-2.0 µg/ml (r² = 0.9999). At the fortified levels of 0.02, 0.05, 0.2 mg/kg, the mean recoveries of praziquantel ranged from 75% to 85%, while the intra-day and inter-day coefficient of variation (CV) of the assay were all less than 9%.
Assuntos
Anti-Helmínticos/análise , Cromatografia Líquida de Alta Pressão/métodos , Músculo Esquelético/química , Praziquantel/análise , Animais , BovinosRESUMO
OBJECTIVE: To compare characteristics of better responders to new regimen therapy with non-responders. METHODS: In a 12-week, two-center, open, parallel group clinical trial, 80 type 2 diabetic patients treated with twice-daily premixed 30 R insulin with or without OAD (s) [fasting blood glucose (FBG) 7.8 - 16.7 mmol/L, HbA1c 7% - 10%] were randomized to once-daily morning insulin glargine plus glimepiride 3 mg or premixed 30 R insulin (70/30) twice-daily plus glimepiride 3 mg. Insulin dosage was titrated to target FBG
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Insulina/análogos & derivados , Administração Oral , Adulto , Idoso , Diabetes Mellitus Tipo 2/sangue , Vias de Administração de Medicamentos , Feminino , Hemoglobinas Glicadas/metabolismo , Humanos , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem , Insulina/uso terapêutico , Insulina Isófana/administração & dosagem , Insulina Isófana/uso terapêutico , Insulina de Ação Prolongada , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
OBJECTIVE: To study the relationship between hepatic insulin resistance induced by high fat diet and the expression of genes involving hepatic glucose output. METHODS: Normal 8-week-old male SD rats were randomly divided into two groups, i.e, normal chow group (NC, n = 10) and high fat diet group (HF, n = 10). They were fed for 28 weeks. Body weight and fasting blood glucose (FBG) were measured. At the end of the experiment, the rats were sacrificed and their fasting insulin (INS) and triglycerides (TG) were measured. Hepatic insulin sensitivity was measured by tissue uptake of 3H-2-deoxyglucose and the content of hepatic glycogen was measured using the anthrone method. Gene expression was investigated by using the semi-quantitative RT-PCR method. RESULTS: As compared with NC group, CF group rats developed visceral obesity which was accompanied by higher plasma TG. FBG in CF group increased starting from the 18th week (NC 4.77+/-63 mmol/L vs HF 5.45+/-87 mmol/L, P < 0.05). The rate of uptake of 3H-2-deoxyglucose in livers decreased by 51% in the HF group. The content of hepatic glycogen increased by 92.4% (P < 0.01). The level of phosphoenolpyruvate carboxykinase (PEPCK) and PGC-1a mRNA increased by 41.5% and 30.8%, respectively (P < 0.05). CONCLUSION: A high fat diet induced expressions of PGC-1a and PEPCK. It suggests that gluconeogenesis may play a role in the increase of hepatic glucose output and FBG.
Assuntos
Glucose/metabolismo , Resistência à Insulina , Glicogênio Hepático/metabolismo , Fígado/metabolismo , Animais , Gorduras na Dieta , Regulação da Expressão Gênica , Proteínas de Choque Térmico/metabolismo , Resistência à Insulina/genética , Masculino , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Fosfoenolpiruvato Carboxiquinase (ATP)/metabolismo , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Fatores de Transcrição/metabolismoRESUMO
OBJECTIVE: To investigate the relationship between the expression of phosphoenolpyruvate carboxykinase (PEPCK) gene and insulin resistance induced by high-fat diet and the effect of rosiglitazone, a thiazolidinedione drug. METHODS: Sixty-three normal 8-week-old male SD rats were randomly divided into 2 groups: short-term group, n = 33, to be fed for 8 weeks and re-divide into 3 equal subgroups: standard chow diet subgroup (NC subgroup fed with standard chow diet), high-fat diet subgroup (HF subgroup, to be fed with lard), and high-fat diet with rosiglitazone subgroup (HF + rosiglitazone subgroup); and long-term group, n = 30, to be fed for 28 weeks, and re-divided into 3 corresponding 3 subgroups: By the end of experiment, serum samples were collected to examine the blood glucose (BG), triglyceride (TG) and free fatty acid (FFA). At the end of the experiment the rats were killed and the visceral adipose tissue was taken out to be weighed, and the liver, muscle, and epididymis were isolated. Glucose infusion rate (GIR) methods and tissue uptake of (3)H-2-deoxyglucose were used to short-and long-term groups evaluate the insulin sensitivity. PEPCK gene expression was investigated to detect the expression of PEPCK mRNA by using semi-quantitative RT-PCR method. RESULTS: In the short-term group, the serum FFA and TG of the HF + rosiglitazone subgroup were lower by 24.5% and 54.0% respectively compared with those the HF subgroup (both P < 0.01). In the long-term group, the serum TG of the HF subgroup was higher by 32.4% in comparison with that of the NC subgroup (P < 0.05), and the serum FFA and TG of the HF + rosiglitazone subgroup were lower by 49.5% and 23.0% respectively compared with those of the HF subgroup (both P < 0.0). In the short-term group the GIR of the HF subgroup was lower by 51.25% in comparison with that of the NC subgroup (P < 0.01). And the GIR of the HF + rosiglitazone subgroup was higher by 149.6% than that of the HF group (P < 0.01). In the long-term group, the rate of uptake of (3)H-2-deoxyglucose in liver, muscle and adipose tissue of the HF subgroup were lower by 42.0%, 36.7%, and 48.1% respectively than those of the HF subgroup (all P < 0.01), and the rate of uptake of 3H-2-deoxyglucose in liver, muscle and adipose tissue of the HF + rosiglitazone subgroup were higher by 39.6%, 66.3%, and 66.7% respectively than those of the HF subgroup (all P < 0.01). In the short-term group the adipose PEPCK mRNA expression of the HF subgroup was 89% +/- 13% that of the NC subgroup; and the adipose PEPCK mRNA expression of the HF + rosiglitazone subgroup was 154% +/- 28% that of the NC subgroup, and was higher by 65.4% than that the HF subgroup (P < 0.05). In the long-term group, the adipose PEPCK mRNA expression of the HF + rosiglitazone subgroup was 144% +/- 17% that of the NC subgroup (P < 0.05), and was higher by 43.3% than that of the HF subgroup (P < 0.05). CONCLUSION: Thiazolidinedione drug increases the re-esterification of fatty acids and reduces circulating FFA, and induces the expression of adipose PEPCK which is accompanied by reduction of FFA, thus improving insulin resistance.
Assuntos
Tecido Adiposo/efeitos dos fármacos , Resistência à Insulina , Fosfoenolpiruvato Carboxiquinase (ATP)/genética , Tiazolidinedionas/farmacologia , Tecido Adiposo/enzimologia , Tecido Adiposo/metabolismo , Animais , Glicemia/análise , Gorduras na Dieta/administração & dosagem , Ácidos Graxos não Esterificados/sangue , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Hipoglicemiantes/farmacologia , Masculino , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Rosiglitazona , Fatores de Tempo , Triglicerídeos/sangueRESUMO
OBJECTIVE: To observe the effects of rosiglitazone and metformin in rats on insulin resistance induced by high-fat diet. METHODS: Normal 8-week old male SD rats were divided into four groups. They were normal chow group (NC, n = 11), high-fat diet (HF, n = 11), metformin-treated (HF + Met, n = 11) and rosiglitazone-treated group (HF + Ros, n = 11). Rosiglitazone 3 mg x kg(-1) x d(-1) and metformin 300 mg x kg(-1) x d(-1) were given orally to HF + Ros and HF + Met group, respectively. After feeding for 8 weeks, serum insulin, adiponectin, glucose (BG), triglyceride (TG) and free fatty acid (FFA) were measured in all the rats. Insulin sensitivity was measured with glucose infusion rate (GIR) and determined by using euglycemic-hyperinsulinemic clamp method. RESULTS: High-fat diet induced obesity in SD rats after feeding for 8 weeks. High-fat diet decreased adiponectin level by 43.7% (P < 0.01) and GIR by 51.3% (P < 0.01) as compared with the NC group. Metformin decreased body weight by 8.4% (P < 0.01) and TG level by 40.5% (P < 0.01). Metformin significantly increased GIR by 58.9% (P < 0.01) when compared with the HF group. Rosiglitazone caused an apparent reduction of FFA (-25.3%, P < 0.05) and TG level (-54.0%, P < 0.01). At the same time, rosiglitazone increased adiponectin by 60% (P < 0.01), and improved insulin sensitivity by 149.6% (P < 0.01) as compared with the HF group. CONCLUSIONS: (1) High-fat diet induces insulin resistance in SD rats; this was associated with an increase in visceral fat and a decrease in the level of adiponectin; (2) Metformin treatment improved insulin sensitivity accompanied by a decrease in body weight and TG level; (3) Rosiglitazone treatment ameliorates IR in a greater extent and is accompanied by a reduction of FFA, TG and an increase of adiponectin levels.
Assuntos
Gorduras na Dieta/administração & dosagem , Hipoglicemiantes/farmacologia , Resistência à Insulina , Metformina/farmacologia , Tiazolidinedionas/farmacologia , Animais , Glicemia/efeitos dos fármacos , Glicemia/metabolismo , Insulina/sangue , Masculino , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Rosiglitazona , Resultado do Tratamento , Aumento de Peso/efeitos dos fármacosRESUMO
OBJECTIVE: To investigate the mechanism of all trans retinoid acid (ATRA) inhibition of cell growth and induction of apoptosis in human retinoblastoma Y79 cells. METHODS: Antiproliferating effects of ATRA on Y79 cells were studied by (3)H-thymidine incorporation. Cell cycle analysis was performed by flow cytometry, apoptosis of the ATRA-treated cells was determined by DNA fragmentation analysis and JNK phosphorylation analyzed by Western blot. RESULTS: After 36h treatment of 1 micro mol/L ATRA, (3)H-thymidine incorporation decreased to 40% with Y79 cells arrested in G(0)/G(1) and Sub-G(1) peak appeared. DNA ladder was observed in DNA fragmentation analysis after 36h treatment of ATRA. Curcumin, a JNK blocker, blocked the apoptosis and the growth inhibition induced by ATRA. JNK was phosphorylated in 10 to 20 min. CONCLUSION: ATRA can induce the apoptosis in Y79 cells by phosphorylation of JNK, which suggests that ATRA may have clinical application prospects for treatment of retinoblastoma.